Bristol Myers CEO on Biontech deal: Next new frontier in treatment of cancer

Pharma exec won't commit to selling life-saving drug in U.S. for lower price offered in Canada

Bristol Myers Squibb CEO on $11B cancer drug deal with BioNTech

Feedback on schizophrenia treatment has been great, says Bristol Myers Squibb CEO

Bristol Myers Squibb | Global Patient Week 2023: LinkedIn Live

Chris Boerner shares his thoughts on A New Era of Leadership

We got a number of important drugs from the Celgene acquisition, says Bristol Myers Squibb CEO